New
HealthMore in Health→
ASPEN-06 Phase 2 Trial Tests Evorpacept Combo in HER2-Positive Gastric Cancer
Key Takeaways
- Nature Medicine published the phase 2 portion of the randomized phase 2/3 ASPEN-06 trial on 24 September 2026 (DOI 10.1038/s41591-026-04700-3).
- The trial evaluated evorpacept combined with trastuzumab, ramucirumab and paclitaxel in patients with HER2-positive advanced gastric cancer.
- Evorpacept is an investigational CD47-directed agent designed to remove a don't-eat-me signal and support innate immune clearance of tumor cells.
- Trastuzumab targets HER2, ramucirumab targets VEGFR-2, and paclitaxel is a taxane chemotherapy.
DE
DT Editorial Team··via nature.com